VA
REGN icon

VestGen Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

VestGen Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$300K Sell
414
-1,236
-75% -$946K 0.01% 837
2025
Q4 		$1.27M Buy
+1,650
New +$1.12M 0.05% 314
2025
Q2 		– Sell
-534
Closed -$339K – 606
2025
Q1 		$339K Buy
+534
New +$367K 0.02% 438

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

VestGen Advisors's REGN Position: Q1 2026 in Review

VestGen Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 75% in Q1 2026, selling an estimated $946K and leaving 414 shares worth $300K. The position accounts for 0.01% of the portfolio, ranked #837.

VestGen Advisors first reported a position in REGN in Q1 2025 and has held it in 3 quarters since. The position peaked at $1.27M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • VestGen Advisors held 414 shares of Regeneron Pharmaceuticals worth $300K as of Q1 2026.
  • VestGen Advisors sold 1,236 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $946K.
  • Regeneron Pharmaceuticals made up 0.01% of VestGen Advisors's portfolio in Q1 2026, its #837 holding.
  • VestGen Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • VestGen Advisors's Regeneron Pharmaceuticals position peaked at $1.27M in Q4 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on VestGen Advisors's 13F filing for Q1 2026, filed 14 May 2026.